Amubarvimab, previously known as BRII-196 , represents a crucial advancement in therapeutic development, particularly concerning its potential to neutralize COVID-19. This targeted antibody demonstrates https://opensocialfactory.com/story26249983/amubarvimab-a-in-depth-exploration-into-the-antibody-s-prospects